Felicitex Therapeutics is a drug discovery company focused on developing novel treatments for dormant (quiescent) cancer cells. Their mission is to improve the effectiveness and long-term outcomes of treatments for highly resistant cancers, including hematopoietic, ovarian, pancreatic, colorectal, and lung cancers. The company's unique approach targets the "sleeping niche" of cancer cells, aiming to deprive them of their ability to enter a dormant state and make them more vulnerable to treatment.

Felicitex Therapeutics has made significant progress in their research, with three clinical drug candidates ready for IND enabling studies. Their innovative strategy addresses critical challenges in oncology, including cancer resistance, metastasis, and relapse. By targeting the mechanism of cancer survival and acquired resistance, Felicitex is positioned at the forefront of developing potentially groundbreaking therapies for some of the most challenging forms of cancer.